Welcome to LookChem.com Sign In|Join Free

CAS

  • or

1019544-14-9

Post Buying Request

1019544-14-9 Suppliers

Recommended suppliersmore

  • Product
  • FOB Price
  • Min.Order
  • Supply Ability
  • Supplier
  • Contact Supplier

1019544-14-9 Usage

Check Digit Verification of cas no

The CAS Registry Mumber 1019544-14-9 includes 10 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 7 digits, 1,0,1,9,5,4 and 4 respectively; the second part has 2 digits, 1 and 4 respectively.
Calculate Digit Verification of CAS Registry Number 1019544-14:
(9*1)+(8*0)+(7*1)+(6*9)+(5*5)+(4*4)+(3*4)+(2*1)+(1*4)=129
129 % 10 = 9
So 1019544-14-9 is a valid CAS Registry Number.

1019544-14-9Relevant articles and documents

Development of novel β-carboline-based hydroxamate derivatives as HDAC inhibitors with DNA damage and apoptosis inducing abilities

Liu, Ji,Wang, Tingting,Wang, Xinyang,Luo, Lin,Guo, Jing,Peng, Yanfu,Xu, Qibing,Miao, Jiefei,Zhang, Yanan,Ling, Yong

, p. 1213 - 1219 (2017)

A series of novel β-carboline-based hydroxamate derivatives (8a-n) as HDAC inhibitors have been designed and synthesized. Most of these compounds displayed potent histone deacetylase inhibitory effects and good antiproliferative activity with IC50/s

Reductive Amination Revisited: Reduction of Aldimines with Trichlorosilane Catalyzed by Dimethylformamide─Functional Group Tolerance, Scope, and Limitations

Campbell, Joanna L. P.,Davies, Christopher D.,Ho?ek, Jan,Ko?ovsky, Pavel,Kysilka, Ond?ej,Popov, Kirill K.,Pour, Milan

, p. 920 - 943 (2022/01/27)

Aldimines, generated in situ from aliphatic, aromatic, and heteroaromatic aldehydes and aliphatic, aromatic, and heteroaromatic primary or secondary amines, can be reduced with trichlorosilane in the presence of dimethylformamide (DMF) as an organocatalys

Rational Design of Suprastat: A Novel Selective Histone Deacetylase 6 Inhibitor with the Ability to Potentiate Immunotherapy in Melanoma Models

Noonepalle, Satish,Shen, Sida,Ptá?ek, Jakub,Tavares, Maurício T.,Zhang, Guiping,Stránsky, Jan,Pavlí?ek, Ji?í,Ferreira, Glaucio M.,Hadley, Melissa,Pelaez, Guido,Ba?inka, Cyril,Kozikowski, Alan P.,Villagra, Alejandro

, p. 10246 - 10262 (2020/11/02)

Selective inhibition of histone deacetylase 6 (HDAC6) is being recognized as a therapeutic approach for cancers. In this study, we designed a new HDAC6 inhibitor, named Suprastat, using in silico simulations. X-ray crystallography and molecular dynamics simulations provide strong evidence to support the notion that the aminomethyl and hydroxyl groups in the capping group of Suprastat establish significant hydrogen bond interactions, either direct or water-mediated, with residues D460, N530, and S531, which play a vital role in regulating the deacetylase function of the enzyme and which are absent in other isoforms. In vitro characterization of Suprastat demonstrates subnanomolar HDAC6 inhibitory potency and a hundred- to a thousand-fold HDAC6 selectivity over the other HDAC isoforms. In vivo studies reveal that a combination of Suprastat and anti-PD1 immunotherapy enhances antitumor immune response, mediated by a decrease of protumoral M2 macrophages and increased infiltration of antitumor CD8+ effector and memory T-cells.

Post a RFQ

Enter 15 to 2000 letters.Word count: 0 letters

Attach files(File Format: Jpeg, Jpg, Gif, Png, PDF, PPT, Zip, Rar,Word or Excel Maximum File Size: 3MB)

1

What can I do for you?
Get Best Price

Get Best Price for 1019544-14-9